Efficacy of Postoperative Blood Salvage Following Total Hip Arthroplasty in Patients with and without Deposited Autologous Units*

Does Single Use of an Autologous Transfusion System in TKA Reduce the Need for Allogenic Blood?: A Prospective Randomized Trial

“…Our results verified no reduction in the need for postoperative ABT by using OrthoPAT 1 as a retransfusion device for WSB. This is in contrast to some studies [7,11,20,22,24,34] reporting a decreased requirement for ABT with a lower risk of transfusionassociated complications and economic benefit using one of several autologous retransfusion devices (OrthoPAT . In contradiction to our data, del Trujillo et al postulated a lower ABT rate for patients undergoing THAs who were treated with the OrthoPAT 1 retransfusion device [7].…”

“…Therefore a reliable comparison with our results is not possible (Table 3). In addition, the retrospective study design [11], the comparison of a prospective study group with a retrospective control group [22], or the missing randomization procedure in a prospective published trial [7], all postulating a lower ABT rate for the reinfusion group, are critical limitations and therefore not directly comparable to our prospective, randomized study. Some previous studies that have noted only a small or no benefit in reducing the need for postoperative ABT evaluated a retransfusion device for USB [17,18,23,30].…”

“…Some previous studies that have noted only a small or no benefit in reducing the need for postoperative ABT evaluated a retransfusion device for USB [17,18,23,30]. Even when trials reported a lower ABT rate for the autologous retransfusion group, they either found no difference in administered ABT units per patient [7,20,34] or the ABT number per patient transfused was not analyzed [11,22,34] (Table 3). We believe patient blood management of individual patients would be more likely to reduce the number of administered ABT units in the retransfused and control groups than using an autologous retransfusion device.…”

“…This contrasts with the report of Amin et al [1], who found no benefit of using Bellovac ABT 1 for only TKAs. Grosvenor et al [11], Munoz et al [22], and Smith et al [34] suggested a decreased ABT rate for patients treated with autologous retransfusion systems. However, these studies Evaluation of an Autologous Transfusion System 1323 used different retransfusion devices for TKAs and THAs.…”

“…Smith et al [34] measured hemoglobin values immediately after surgery. Grosvenor et al [11] provided no postoperative hemoglobin levels for the reinfusion and control groups. Therefore a reliable comparison to our results was not possible (Table 3).…”